The GOT-IT Trial contains a centrally-managed cross centre dataset which is available, upon request, from the Digital Curation Centre within the University of Edinburgh. Data requests can be made at <crh-data-manager@ed.ac.uk>.

Introduction {#sec008}
============

Retained placenta following childbirth complicates 0.1%--2% of deliveries \[[@pmed.1003001.ref001]\]. Without prompt treatment, it results in significant haemorrhage, which can result in maternal death. Current treatment for retained placenta is the surgical procedure of manual removal of placenta (MROP) or uterine curettage, which has attendant risks including bleeding and infection. This procedure is not available in all settings, particularly in low- and middle-income countries, where retained placenta has a high morbidity and mortality rate \[[@pmed.1003001.ref002],[@pmed.1003001.ref003]\]. There is therefore a need for an effective, acceptable, safe, and affordable medical treatment for retained placenta that is suitable for all settings.

Small studies have suggested that nitric oxide donors such as nitroglycerin (also known as glyceryl trinitrate) may be an effective treatment for retained placenta \[[@pmed.1003001.ref004]\]. Six studies (5 case series \[[@pmed.1003001.ref005]--[@pmed.1003001.ref009]\] and 1 small placebo-controlled randomised trial \[[@pmed.1003001.ref010]\]) have reported that administration of nitroglycerin intravenously \[[@pmed.1003001.ref005],[@pmed.1003001.ref006],[@pmed.1003001.ref008],[@pmed.1003001.ref009]\] or via a sublingual tablet \[[@pmed.1003001.ref007],[@pmed.1003001.ref010]\] is effective in relaxing the uterus to facilitate insertion of the examining hand for MROP \[[@pmed.1003001.ref005],[@pmed.1003001.ref006],[@pmed.1003001.ref008],[@pmed.1003001.ref009]\] or in facilitating delivery of the placenta by controlled cord traction \[[@pmed.1003001.ref007],[@pmed.1003001.ref010]\]. However, these findings were not replicated in 2 other studies in which nitroglycerin (intravenous \[[@pmed.1003001.ref011]\] or sublingual tablet \[[@pmed.1003001.ref012]\]) was not effective in medical treatment of retained placenta.

If nitroglycerin is to be effective for medical management of retained placenta, it must be able to address at least 1 of the underlying pathophysiological mechanisms. In placentae that are detached but trapped behind a myometrial constriction ring, nitroglycerin could potentially relax local uterine muscle constriction, thereby effecting placental release. In adherent placenta, Farley et al. have suggested that nitric-oxide-mediated contraction and relaxation of human chorionic villi along their longitudinal axis might serve as a nitroglycerin-mediated mechanism for placental separation \[[@pmed.1003001.ref013]\]. Where the placenta is morbidly adherent to the myometrium, currently available nitric oxide donor drugs (including nitroglycerin) are unlikely to effect release, and surgical management is likely to remain the mainstay of treatment. In summary, although there are signals that nitroglycerin may have potential to medically treat retained placenta, there is a need to undertake a high-quality randomised, placebo-controlled, multicentre, double-blind trial to definitively determine whether nitroglycerin is or is not effective in medically managing retained placenta \[[@pmed.1003001.ref005]--[@pmed.1003001.ref009],[@pmed.1003001.ref014]--[@pmed.1003001.ref017]\].

The GOT-IT (Glyceryl Trinitrate for Retained Placenta) trial was a large multi-centre trial that aimed to determine the clinical effectiveness and cost-effectiveness of sublingual nitroglycerin (glyceryl trinitrate) spray compared with placebo in reducing the need for MROP in women with retained placenta after vaginal delivery.

Methods {#sec009}
=======

Study design and oversight {#sec010}
--------------------------

The GOT-IT trial was funded by the UK National Institute for Health Research Health Technology Assessment Programme in response to a specific commissioned grant call. Details of the trial protocol ([S1 Text](#pmed.1003001.s010){ref-type="supplementary-material"}) and statistical analysis plan ([S2 Text](#pmed.1003001.s011){ref-type="supplementary-material"}) have been published previously \[[@pmed.1003001.ref018]\]. The North East--Newcastle and North Tyneside 2 Research Ethics Committee (13/NE/0339) approved the trial. A trial steering committee (TSC) and independent data monitoring committee (iDMC) provided trial oversight ([S3 Text](#pmed.1003001.s012){ref-type="supplementary-material"}). Information about the trial was made available to women during pregnancy. Clinical staff approached eligible women with retained placenta, and, following discussion, informed written consent---or oral consent followed up by written consent as soon as possible---was obtained from women who were interested in taking part in the trial. Further details about the consent and recruitment processes and the steps taken to ensure that participants gave truly informed consent are provided in the trial protocol ([S1 Text](#pmed.1003001.s010){ref-type="supplementary-material"}). The authors vouch for the accuracy and completeness of the data and for the fidelity of the trial to the protocol. This study is reported as per the Consolidated Standards of Reporting Trials (CONSORT) guideline ([S1 Checklist](#pmed.1003001.s001){ref-type="supplementary-material"}). The trial was registered in the ISRCTN registry (<http://www.isrctn.com/>, ISCRTN88609453).

Trial setting and patients {#sec011}
--------------------------

From 1 October 2014 to 31 July 2017, women diagnosed with retained placenta following vaginal delivery were identified and screened for eligibility by clinical staff in delivery wards in 29 maternity hospitals in England and Scotland, UK ([S1 Table](#pmed.1003001.s003){ref-type="supplementary-material"}). Maternity units were selected based on their ability to undertake an intrapartum research study, and included both teaching hospitals and district general hospitals, with delivery numbers ranging from approximately 1,000 per annum to \>7,000 per annum.

Women were eligible for the trial if, following vaginal birth, they sustained a retained placenta and were at risk of needing MROP. A retained placenta was defined according to National Institute for Health and Care Excellence guidelines as the placenta remaining undelivered after 30 minutes of active management of the third stage of labour \[[@pmed.1003001.ref019]\].

Women were eligible if they delivered at \>14 weeks gestation, were ≥16 years of age, and were haemodynamically stable (defined as heart rate ≤ 119 beats per minute \[bpm\] and systolic blood pressure \> 100 mm Hg).

We excluded women with suspected placenta accreta/increta/percreta; allergy, hypersensitivity, or contraindication to nitrates; alcohol consumption within the past 24 hours; instrumental vaginal delivery in an operating theatre; multiple pregnancy in the index pregnancy; or inability to give informed consent or who were taking phosphodiesterase inhibitor.

Women were given information about the trial antenatally. Eligible women with retained placenta were approached by clinical staff, and, following discussion, informed written consent---or oral consent followed up by written consent as soon as possible---was obtained from women who indicated willingness to take part in the trial. Further details about these processes are provided in the trial protocol ([S1 Text](#pmed.1003001.s010){ref-type="supplementary-material"}) \[[@pmed.1003001.ref018]\] and qualitative research publications \[[@pmed.1003001.ref020]--[@pmed.1003001.ref022]\]. Baseline demographics, including maternal age, body mass index (BMI), smoking status, ethnicity, and alcohol use, were obtained from the antenatal booking record by the local research teams ([Table 1](#pmed.1003001.t001){ref-type="table"}).

10.1371/journal.pmed.1003001.t001

###### Baseline characteristics of study participants.

![](pmed.1003001.t001){#pmed.1003001.t001g}

  Characteristic                            Nitroglycerin (*N* = 541)   Placebo (*N* = 563)
  ----------------------------------------- --------------------------- ---------------------
  Age (years)---mean (SD); *n*              30.6 (5.5); 541             30.8 (5.1); 563
  BMI (kg/m^2^)---mean (SD); *n*            25.8 (5.4); 526             25.4 (5.2); 548
  Smoker                                                                
      Current smoker                        75 (13.9)                   77 (13.7)
      Ex-smoker                             101 (18.7)                  98 (17.4)
      Never smoker                          350 (64.7)                  376 (66.8)
      Missing                               15 (2.8)                    12 (2.1)
  Alcohol use in pregnancy                                              
      Yes                                   19 (3.5)                    18 (3.2)
      No                                    505 (93.3)                  521 (92.5)
      Missing                               17 (3.1)                    24 (4.3)
  Ethnicity                                                             
      White                                 468 (86.5)                  487 (86.5)
      Asian                                 38 (7.0)                    41 (7.3)
      Black                                 7 (1.3)                     8 (1.4)
      Mixed                                 5 (0.9)                     6 (1.1)
      Chinese                               5 (0.9)                     6 (1.1)
      Other                                 5 (0.9)                     6 (1.1)
      Missing                               13 (2.4)                    9 (1.6)
  Blood pressure (mm Hg)---mean (SD); *n*                               
      Systolic                              123.8 (12.8); 538           124.6 (12.6); 559
      Diastolic                             73.3 (10.2); 535            75.1 (10.1); 559
  Heart rate (bpm)---mean (SD); *n*         84.6 (13.0); 539            84.7 (12.9); 559
  Temperature (°C)---mean (SD); *n*         36.8 (0.5); 513             36.9 (0.4); 534
  Haemoglobin (mmol/l)---mean (SD); *n*     7.6 (0.8); 468              7.6 (0.9); 478
  Previous pregnancy                        311 (57.5)                  323 (57.4)
  Previous retained placenta                48 (15.4)                   57 (17.6)
  Previous placenta praevia/accreta         4 (1.3)                     1 (0.3)

Values are *n* (%) unless otherwise stated.

bpm, beats per minute.

Randomisation and masking {#sec012}
-------------------------

We randomly assigned participants (1:1) to nitroglycerin or placebo. Study medication was provided in pre-packed randomised permuted blocks and stored in temperature-controlled storage areas in delivery rooms. Study drug and placebo were manufactured by Pharmasol and labelled by Sharp Clinical Services (UK). Once a participant was recruited, the study drug was allocated by taking the next available treatment pack from the shelf. Both clinicians and participants were blinded to the treatment allocation.

Trial interventions {#sec013}
-------------------

Baseline observations (maternal blood pressure \[mm Hg\] and heart rate \[bpm\]) were taken prior to study drug administration. If eligibility was confirmed, women self-administered 2 puffs of sublingual nitroglycerin (800 μg; intervention) or placebo spray (control). Maternal temperature (°C) and haemoglobin were measured at baseline, with heart rate, systolic blood pressure, and temperature being recorded at 5 and 15 minutes after study drug administration. If the placenta remained undelivered at 15 minutes after study drug administration, the decision was made to proceed with MROP as soon as possible.

A haemoglobin sample was collected on the first postnatal day. Questionnaires were completed prior to hospital discharge (patient satisfaction and side effects) and at 6 weeks post-delivery (patient satisfaction, side effects, and health resource use) ([S4](#pmed.1003001.s013){ref-type="supplementary-material"} and [S5](#pmed.1003001.s014){ref-type="supplementary-material"} Texts).

Trial outcomes {#sec014}
--------------

The primary clinical outcome was the need for MROP, i.e., the placenta remaining undelivered 15 minutes after study treatment and/or MROP being required within 15 minutes of treatment due to safety concerns. The primary safety outcome was measured blood loss between study drug administration and transfer to the postnatal ward or other clinical area. Blood loss was measured using the routine clinical methods used at study sites, and was categorised as \<500 ml, 500--1,000 ml, or \>1,000 ml by local investigators. The primary patient-sided outcomes were satisfaction with treatment and side-effect profile, assessed by questionnaires pre-discharge (satisfaction and treatment-associated side effects) and at 6 weeks post-delivery (satisfaction, side effects in the 6 weeks following delivery, and health resource use). The primary economic outcome was a comparison of the use of nitroglycerin versus standard practice by evaluating the net incremental costs to the UK National Health Service.

Secondary clinical outcomes were fall in haemoglobin of \>15% between randomisation and the first postnatal day; time from randomisation to delivery of placenta; MROP in theatre; need for earlier than planned MROP due to clinical condition; fall in systolic or diastolic blood pressure of \>15 mm Hg and/or increase in heart rate of \>20 bpm between baseline and 5 and 15 minutes after administration of treatment; need for blood transfusion between time of delivery and discharge from hospital; need for general anaesthesia; maternal pyrexia (1 or more temperature readings of \>38°C prior to discharge from hospital, or in the first 72 hours after delivery, if hospital stay was longer than 72 hours); and sustained uterine relaxation after removal of placenta requiring uterotonics.

Safety, adverse event monitoring, and trial management {#sec015}
------------------------------------------------------

All reported adverse events were documented in the participants' clinical records and collated and coded by the trial office, which was located in the Queen's Medical Research Institute at the University of Edinburgh. The trial office comprised the trial manager and trial administrator. The trial office was responsible for the day-to-day running of the trial and worked closely with the Centre for Healthcare Randomised Trials at the University of Aberdeen. The chief investigator (FCD) had regular oversight of the trial office.

All serious adverse events were reported by the principal site investigator to the sponsor and the trial office, and also entered into the electronic database within 24 hours of the site becoming aware of the event. The chief investigator was notified of all severe adverse event reports, and all events were followed up until resolution. The TSC and iDMC reviewed the serious adverse events at regular meetings every 6 months, with the latter reviewing the data unblinded. If any serious concerns had arisen about trial safety, the chair of the iDMC would have recommended to the chair of the TSC that the study should be discontinued. Finally, our lay advisors were involved throughout study, with their advice influencing the trial design and delivery, and informing project management group and TSC discussions.

Statistical analyses {#sec016}
--------------------

From discussions with clinicians and women, we determined that an absolute benefit (i.e., reduction in the need for MROP) of 10% would be the minimum required to make it worth implementing the intervention (nitroglycerin spray) in practice. We therefore took a statistical approach to the control (placebo) rate, setting this at 50% because, from a statistical perspective, this corresponds to the highest variability in a yes/no (binary) outcome, and hence generates the largest maximum sample size required to demonstrate an absolute 10% difference. That meant that we could be confident that if the observed control rate was higher or lower, our study would be sufficiently powered to detect a 10% absolute difference and potentially adequately powered to detect smaller absolute differences.

Due to considerable uncertainties in the untreated rate and expected treatment effect, we adopted a group sequential design with 5 interim analyses, allowing the iDMC the flexibility to end the study if there was overwhelming evidence of benefit or futility. Allowing for 5 interim analyses, 90% power, and 5% significance level, a maximum sample size of 1,078 participants was needed to demonstrate a 10% change in rate, from 50% on placebo to 40% on nitroglycerin spray. We used a Lan--DeMets alpha spending approach \[[@pmed.1003001.ref023]\] with O'Brien--Fleming boundaries \[[@pmed.1003001.ref024]\]. We specified a 2-sided test, with efficacy and futility boundaries (only for the third interim analysis) and 5 interim reviews by the iDMC, equally spaced at 215, 429, 644, 858, and 1,073 randomised participants with primary outcome data. Analysis was based on the intention-to-treat (ITT) principle. Statistical significance was at the 2-sided 5% level, with the working level of significance set at *p* = 0.0481.

The group sequential design for the primary clinical outcome was analysed using logistic regression with no adjustment for centre, using East 6.4.1 (2016) \[[@pmed.1003001.ref025]\]. The primary safety outcome was analysed using ordered logistic regression, and patient-sided outcomes were analysed using logistic regression, accounting for centre using cluster robust standard errors. Secondary clinical outcomes were analysed using logistic or linear regression, as appropriate. Continuous variables were summarised with mean and standard deviation, and discrete variables were summarised as absolute number and percentage. The remainder of the analysis was undertaken using Stata 14 \[[@pmed.1003001.ref026]\]. Pre-specified subgroup analyses (previous cesarean section and gestation at delivery \<36 and ≥36 weeks) were conducted using a stricter 2-sided 1% level of statistical significance. A post hoc analysis looked at serious adverse events and was conducted using logistic regression adjusting for centre.

A cost analysis was undertaken to quantify the difference in mean costs between the nitroglycerin and placebo arm. Research costs associated with placebo delivery were factored out of the analysis to estimate the incremental cost (or cost savings) of the active intervention versus standard practice. Resource use associated with the alternative management strategies was estimated from the time of randomisation to 6 weeks postpartum. Resources included staff time for providing study drug to patients, additional resource use associated with complications arising following administration of study drug, subsequent costs associated with delivery of the placenta, costs associated with postnatal stay (to discharge), and costs associated with subsequent health service contact relating to retained products of conception up to 6 weeks post-delivery. National unit price data were used to attach costs to the different elements of resource use ([S2 Table](#pmed.1003001.s004){ref-type="supplementary-material"}) \[[@pmed.1003001.ref027]--[@pmed.1003001.ref031]\]. Mean costs were summarised by treatment allocation group, and the incremental cost (or cost savings) associated with the use of nitroglycerin was estimated using linear regression with cluster robust standard errors.

Results {#sec017}
=======

Patients {#sec018}
--------

From October 2014 through July 2017, 1,671 women were screened, 564 were excluded, and 1,107 (66%) women were subsequently consented and randomly assigned, 564 to placebo and 543 to nitroglycerin ([Fig 1](#pmed.1003001.g001){ref-type="fig"}).

![CONSORT diagram for GOT-IT trial.\
^1^Reasons for post-randomisation exclusions were (1) eligibility could not be confirmed as the last observations were taken approximately 1 hour prior to the study drug being given; (2) the inclusion criteria observations were not documented; and (3) the participant consent form was lost and there were no eligible observations documented.](pmed.1003001.g001){#pmed.1003001.g001}

Of the 1,671 women screened, 353 were ineligible, 63 declined, 60 were missed, and it was not appropriate to approach 7 patients ([S3 Table](#pmed.1003001.s005){ref-type="supplementary-material"}). A further 81 eligible women were excluded prior to randomisation, and 3 participants were excluded post-randomisation (2 in the nitroglycerin arm and 1 in the placebo arm), making the ITT analysis set 541 in the nitroglycerin arm versus 563 in the placebo arm. Twelve participants did not receive the study drug (6 in the nitroglycerin arm and 7 in the placebo arm) ([S4 Table](#pmed.1003001.s006){ref-type="supplementary-material"}). In total, 390 participants in the nitroglycerin arm and 399 in the placebo arm filled in the pre-discharge questionnaire. At the 6-week follow-up, 228 participants in the nitroglycerin arm and 241 in the placebo arm returned the questionnaire. The baseline characteristics of participants in the ITT population were balanced across the 2 allocated groups ([Table 1](#pmed.1003001.t001){ref-type="table"}).

Primary outcomes {#sec019}
----------------

The trial was not stopped early at any of the interim analysis stages, as none of the stopping boundaries were crossed. These boundaries were generated assuming a control rate of 50%. In practice, the control rate was never less than 90%. The TSC and iDMC (which had seen unblinded data) had a series of discussions about re-estimating the sample size and changing the timings of the interim analyses, but the unanimous decision was to carry on unaltered. The rationale was that there did not seem to be any emerging safety concerns, recruitment was going well, and therefore the original sample size should be maintained to (1) get precise estimates of any treatment effect (or lack of it) and (2) have as much power as possible for secondary outcomes and the economic evaluation, particularly given that more participants than expected were progressing on blinded data to MROP ([S1 Fig](#pmed.1003001.s002){ref-type="supplementary-material"}). The trial therefore recruited to its maximum size of 1,104 randomised.

There was no statistically significant or clinically meaningful difference in the primary clinical outcome (need for MROP by 15 minutes) between the 2 groups (505 \[93.3%\] for nitroglycerin versus 518 \[92.0%\] for placebo, odds ratio \[OR\] 1.01 \[95% CI 0.98 to 1.04\], *p* = 0.39) ([Table 2](#pmed.1003001.t002){ref-type="table"}). For participants where the placenta was delivered after 15 minutes, the majority had MROP (nitroglycerin, 407 \[80.6%\]; placebo, 417 \[80.5%\]; unadjusted OR 1.00 \[95% CI 0.83--1.20\], *p* = 0.97) ([S5 Table](#pmed.1003001.s007){ref-type="supplementary-material"}).

10.1371/journal.pmed.1003001.t002

###### Primary clinical, safety, and patient-sided outcomes.

![](pmed.1003001.t002){#pmed.1003001.t002g}

  Outcome                                                             Nitroglycerin (*N* = 541)   Placebo (*N* = 563)   Odds ratio (95% CI)   *p*-Value
  ------------------------------------------------------------------- --------------------------- --------------------- --------------------- -----------
  **Primary clinical outcome**[\*](#t002fn002){ref-type="table-fn"}                                                                           
  Placenta delivered within 15 minutes                                36/541 (6.7)                45/563 (8.0)                                
  Placenta not delivered within 15 minutes                            505/541 (93.3)              518/563 (92.0)        1.01 (0.98, 1.04)     0.39
  **Primary safety outcome: blood loss**                                                                                                      
  \<500 ml                                                            238/537 (44.3)              249/560 (44.5)                              
  500--1,000 ml                                                       180/537 (33.5)              224/560 (40.0)                              
  \>1,000 ml                                                          119/537 (22.2)              87/560 (15.5)         1.14 (0.88, 1.48)     0.31
  **Primary patient-sided outcomes**                                                                                                          
  Recommend study drug to a friend/relative?                                                                                                  
  **    Pre-discharge**                                                                                                                       
      No                                                              94/382 (24.6)               85/388 (21.9)                               
      Yes                                                             288/382 (75.4)              303/388 (78.1)        0.87 ((0.62, 1.22)    0.41
  **    6 weeks**                                                                                                                             
      No                                                              55/221 (24.9)               60/238 (25.2)                               
      Yes                                                             166/221 (75.1)              178/238 (74.8)        1.02 (0.66, 1.56)     0.94
  Feeling sick                                                                                                                                
  **    Pre-discharge**                                                                                                                       
      No                                                              299/377 (79.3)              323/384 (84.1)                              
      Yes                                                             78/377 (20.7)               61/384 (15.9)         1.37 (0.94, 1.99)     0.10
  **    6 weeks**                                                                                                                             
      No                                                              180/211 (85.3)              206/232 (88.8)                              
      Yes                                                             31/211 (14.7)               26/232 (11.2)         1.40 (0.80, 2.47)     0.23
  Palpitations/heart racing                                                                                                                   
  **    Pre-discharge**                                                                                                                       
      No                                                              332/368 (90.2)              360/375 (96.0)                              
      Yes                                                             36/368 (9.8)                15/375 (4.0)          2.60 (1.40, 4.84)     0.003
  **    6 weeks**                                                                                                                             
      No                                                              186/200 (93.0)              215/225 (95.6)                              
      Yes                                                             14/200 (7.0)                10/225 (4.4)          1.62 (0.70, 3.73)     0.25

Values are *n/N* (%).

\*This analysis was adjusted for multiple looks at the data in accordance with the group sequential design.

There was no statistically significant or clinically meaningful difference in the primary safety outcome of blood loss between groups (\<500 ml: nitroglycerin, 238 \[44.3%\], versus placebo, 249 \[44.5%\]; 500--1,000 ml: nitroglycerin, 180 \[33.5%\], versus placebo, 224 \[40.0%\]; \>1,000 ml: nitroglycerin, 119 \[22.2%\], versus placebo, 87 \[15.5%\]; ordinal OR 1.14 \[95% CI 0.88--1.48\], *p* = 0.31) ([Table 2](#pmed.1003001.t002){ref-type="table"}).

There was no statistically significant or clinically meaningful difference in the primary patient-sided satisfaction outcome of recommending the study drug to a friend/relative at pre-discharge (nitroglycerin, 288 \[75.4%\], versus placebo, 303 \[78.1%\]; OR 0.87 \[95% CI 0.62--1.22\], *p* = 0.41) or at 6 weeks (nitroglycerin, 166 \[75.1%\], versus placebo, 178 \[74.8%\]; OR 1.02 \[95% CI 0.66--1.56\], *p* = 0.94). For the primary patient-sided side-effect outcome, participants who received nitroglycerin were more likely to report palpitations/heart racing prior to discharge (nitroglycerin, 36 \[9.8%\], versus placebo, 15 \[4.0%\]; OR 2.60 \[95% CI 1.40--4.84\], *p* = 0.003). There was no statistically significant difference in palpitations/heart racing by 6 weeks postnatal (nitroglycerin, 31 \[14.7%\], versus placebo, 26 \[11.2%\]; OR 1.40 \[95% CI 0.80--2.47\]; *p* = 0.24) and no statistically significant difference in feeling sick pre-discharge or at 6 weeks between the 2 groups ([Table 2](#pmed.1003001.t002){ref-type="table"}).

Health service resource use per patient is summarised by treatment allocation group in [S6 Table](#pmed.1003001.s008){ref-type="supplementary-material"}. [Table 3](#pmed.1003001.t003){ref-type="table"} summarises the associated mean health service costs by treatment allocation, along with the estimated difference between groups. There were no statistically significant differences between the groups in any of the cost categories, although hospital episode costs were non-statistically-significantly higher in the nitroglycerin arm, which was driven by a slightly higher MROP rate.

10.1371/journal.pmed.1003001.t003

###### Difference in NHS per-patient costs by category and treatment allocation (intention to treat).

![](pmed.1003001.t003){#pmed.1003001.t003g}

  Category                                               Number of observations[^a^](#t003fn001){ref-type="table-fn"}   Cost (£), mean (SD) (*N* = 1,104)   Mean difference in cost (£) (95% CI)[^b^](#t003fn002){ref-type="table-fn"}   
  ------------------------------------------------------ -------------------------------------------------------------- ----------------------------------- ---------------------------------------------------------------------------- ---------------------------
  Total episode cost                                     966                                                            1,366.62 (733.61)                   1,317.12 (642.42)                                                            49.50 (−42.63 to 141.64)
  Total primary care cost                                424                                                            25.13 (52.29)                       28.40 (58.59)                                                                −3.28 (−13.93 to 7.38)
  Cost of outpatient appointment                         466                                                            25.65 (98.42)                       18.86 (63.96)                                                                6.79 (−10.79 to 24.37)
  Cost of hospital readmission                           1,098                                                          52.05 (858.84)                      43.32 (263.98)                                                               8.73 (−61.92 to 79.39)
  Total NHS cost[^c^](#t003fn003){ref-type="table-fn"}   369                                                            1,513.95 (1,732)                    1,458.65 (779)                                                               55.30 (−199.20 to 309.79)

^a^Number of observations with complete data on each cost category.

^b^Cluster robust CIs.

^c^Incorporates total episode cost, total primary care cost, cost of outpatient appointments, and cost of hospital readmissions in individuals with complete data across all categories.

NHS, National Health Service.

Secondary clinical outcomes {#sec020}
---------------------------

Secondary clinical outcomes are shown in [Table 4](#pmed.1003001.t004){ref-type="table"}. Participants in the nitroglycerin group were more likely than those in the placebo group to have a fall in systolic or diastolic blood pressure and/or increase in heart rate between baseline and 5 and 15 minutes post-administration (nitroglycerin, 323 \[60.8%\], versus placebo, 131 \[24.1%\]; OR 4.90 \[95% CI 3.73--6.42\], *p \<* 0.001) and to require a blood transfusion between time of delivery and discharge from hospital (nitroglycerin, 61 \[11.4%\], versus placebo, 43 \[7.8%\]; OR 1.53 \[95% CI 1.04--2.25\], *p* = 0.03). There were no statistically significant or clinically meaningful differences between the groups for any other secondary clinical outcomes. As there was a low event rate for the primary clinical outcome, the number of events in the subgroups was too low to perform the planned subgroup analysis.

10.1371/journal.pmed.1003001.t004

###### Secondary clinical outcomes.

![](pmed.1003001.t004){#pmed.1003001.t004g}

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome                                                                                                                    Nitroglycerin\    Placebo\          Effect size[^a^](#t004fn002){ref-type="table-fn"} (95% CI)   *p*-Value
                                                                                                                             (*N* = 541)       (*N* = 563)                                                                    
  -------------------------------------------------------------------------------------------------------------------------- ----------------- ----------------- ------------------------------------------------------------ -----------
  **Fall in systolic or diastolic blood pressure and/or increase in heart rate**[^**b**^](#t004fn003){ref-type="table-fn"}                                                                                                    

  No                                                                                                                         208/531 (39.2)    413/544 (75.9)                                                                 

  Yes                                                                                                                        323/531 (60.8)    131/544 (24.1)    4.90 (3.73, 6.42)                                            \<0.001

  **Blood transfusion**                                                                                                                                                                                                       

  No                                                                                                                         472/533 (88.6)    508/551 (92.2)                                                                 

  Yes                                                                                                                        61/533 (11.4)     43/551 (7.8)      1.53 (1.04, 2.25)                                            0.03

  **More than 15% fall in haemoglobin**                                                                                                                                                                                       

  No                                                                                                                         160/414 (38.6)    180/421 (42.8)                                                                 

  Yes                                                                                                                        254/414 (61.4)    241/421 (57.2)    1.19 (0.93, 1.52)                                            0.18

  **Time from randomisation to delivery of placenta (mins)**                                                                                                                                                                  

                                                                                                                             12.1 (7.3); 539   12.2 (7.0); 561   −0.19 (−0.94, 0.55)                                          0.60

  **Manual removal of placenta in theatre**                                                                                                                                                                                   

  No                                                                                                                         141/540 (26.1)    152/563 (27.0)                                                                 

  Yes                                                                                                                        399/540 (73.9)    411/563 (73.0)    1.05 (0.80, 1.36)                                            0.74

  **Need for earlier than planned manual removal of placenta**                                                                                                                                                                

  No                                                                                                                         407/416 (97.8)    420/431 (97.4)                                                                 

  Yes                                                                                                                        9/416 (2.2)       11/431 (2.6)      0.84 (0.30, 2.35)                                            0.75

  **General anaesthesia**                                                                                                                                                                                                     

  No                                                                                                                         390/438 (89.0)    398/443 (89.8)                                                                 

  Yes                                                                                                                        48/438 (11.0)     45/443 (10.2)     1.09 (0.66, 1.80)                                            0.74

  **Maternal pyrexia**                                                                                                                                                                                                        

  No                                                                                                                         516/527 (97.9)    530/551 (96.2)                                                                 

  Yes                                                                                                                        11/527 (2.1)      21/551 (3.8)      0.54 (0.26, 1.11)                                            0.09

  **Sustained uterine relaxation**[^**c**^](#t004fn004){ref-type="table-fn"}                                                                                                                                                  

  No                                                                                                                         460/528 (87.1)    482/550 (87.6)                                                                 

  Yes                                                                                                                        68/528 (12.9)     68/550 (12.4)     1.05 (0.76, 1.44)                                            0.77
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values are *n/N* (%) for dichotomous variables and mean (SD); *n* for continuous variables.

^a^Effect sizes are odds ratios apart from time from randomisation to delivery of placenta, which is mean difference.

^b^Defined as fall in systolic or diastolic blood pressure of more than 15 mm Hg and/or increase in heart rate of more than 20 beats per minute between baseline and 5 and 15 minutes post-administration.

^c^Defined as uterine relaxation requiring additional uterotonics.

Safety outcomes {#sec021}
---------------

There were 52 serious adverse events during the trial (nitroglycerin, 27 \[5.0%\]; placebo, 26 \[4.6%\]). The majority required hospitalisation (nitroglycerin, 24; placebo, 26) and were due to postpartum haemorrhage (nitroglycerin, 17; placebo, 12) ([S7 Table](#pmed.1003001.s009){ref-type="supplementary-material"}).

Discussion {#sec022}
==========

To our knowledge, GOT-IT is the largest multi-centre randomised, trial of nitroglycerin for medical treatment of retained placenta in women following vaginal delivery, and was powered to detect an absolute 10% difference in efficacy, assuming an untreated rate of requiring MROP of 50%. In contrast to previous publications suggesting that nitric oxide donors may be an effective treatment for retained placenta \[[@pmed.1003001.ref004],[@pmed.1003001.ref005]--[@pmed.1003001.ref009],[@pmed.1003001.ref010]\], our larger and more robust trial demonstrates that nitroglycerin is ineffective for medical treatment of retained placenta when used with controlled cord traction. There were no statistically significant or clinically meaningful differences in the primary clinical, safety, patient-sided, or economic outcomes, with the observed non-statistically-significant differences in effectiveness and safety outcomes directionally favouring placebo. Secondary clinical outcomes also suggested increased side-effect profile and haemodynamic changes following nitroglycerin administration, with the increased number of blood transfusions signalling possible safety concerns.

We recruited over 1,100 women with an obstetric emergency to a clinical trial of a medicinal product in an acute peripartum setting from a large number of centres of differing size, increasing the generalisability of the results. We achieved our recruitment target ahead of time, and within budget. A key strength of our trial is our flexible group sequential trial design, which enabled us to accommodate uncertainties in the key evidence on which this trial was based, and included the ability to stop the trial if there was evidence of overwhelming efficacy or futility. As none of the efficacy and futility boundaries were crossed at any of the interim analyses, the trial proceeded to recruit to its full sample size, albeit with a dramatically higher event rate than expected (\>90% compared with the assumed 50%). This allowed, in the presence of much lower binomial variability, very precise estimates of the lack of a treatment effect, enabling us to confidently rule out any meaningful clinical benefit from this intervention.

A potential weakness in our trial was the low return rate for the 6-week postnatal questionnaire. Although the return rate improved following implementation of recommendations from qualitative research \[[@pmed.1003001.ref021],[@pmed.1003001.ref022]\], the overall rate remained disappointingly low. We attributed this poor return rate to women having insufficient time to complete and return a questionnaire while caring for a newborn child. There were, however, no differences in return rates between study groups or between women who did and did not have MROP, and the patient-reported use of outpatient and primary care services at 6 weeks accounted for only a small proportion (approximately 5%) of overall health service costs.

Nitroglycerin can be administered either sublingually or intravenously. Both routes of administration have the same pharmacokinetic properties, with the onset of action within 2 to 3 minutes and peak plasma concentrations approximately 6 to 7 minutes post‐dose \[[@pmed.1003001.ref032]\]. We chose to use sublingual spray because, compared to sublingual tablets, the spray has several advantages including significant reduction in latency of onset, fewer objective and subjective side effects, and stability at room temperature \[[@pmed.1003001.ref033]\]. Nitroglycerin spray is also used in other obstetric emergencies where rapid uterine relaxation is required, for example to release a trapped head in cesarean section or breech delivery. We discounted the intravenous route of administration because, although intravenous nitroglycerin has been used to treat retained placenta, the requirement for cannulation limits its generalisability, and the symptomatic hypotension that occurs at higher doses would be potentially dangerous in low- and middle-income settings where options for resuscitation are limited. Although it is possible that our results may have been different if we had used a different route of administration, we believe this is unlikely. Women who received the nitroglycerin were more likely to report palpitations and to have a fall in systolic or diastolic blood pressure and/or increase in heart rate following its administration. This is consistent with the known effects of nitroglycerin and provides evidence that self-administration of the intervention by women was effective in causing a pharmacological effect.

One of the challenges of treating retained placenta is that its pathophysiology remains poorly understood. A retained placenta is a clinical diagnosis that is reported to variously occur when the placenta is detached but trapped, or partially or completely adherent to the underlying myometrium. Although ultrasound has been used in a research setting to try to phenotype retained placentae, its diagnostic accuracy and utility to inform clinical management is not proven. Ultrasound is also not readily available in low- and middle-income settings. We therefore chose a pragmatic approach to trial inclusion, with women being eligible for trial entry if they had a clinical diagnosis of retained placenta. We accept that if different phenotypes of retained placenta do exist that respond differently to different treatments, we may not have been able to identify this in our trial. This may have contributed to our finding that nitroglycerin was ineffective for management of retained placenta.

To inform our trial design, we consulted our lay advisors and clinicians about whether a woman who had had an instrumental vaginal delivery in an operating theatre should be eligible to take part in the trial. Our consultees expressed concerns that it would be undignified and unethical for a woman to remain exposed in a theatre environment whilst waiting for a retained placenta to be diagnosed. They felt that these concerns were less when the instrumental delivery occurred in the delivery room because this was a more private space, where it would easier for those involved in the delivery to maintain the mother's dignity. Given this strong steer, we decided that women with an instrumental vaginal delivery in theatre would not be eligible to take part in the study. The main difference between women having an instrumental vaginal delivery in a delivery room (who were eligible) and in theatre is the setting: We therefore believe that our finding, that nitroglycerin is ineffective for treatment of retained placenta, is generalisable to women with instrumental vaginal delivery in theatre.

A potential safety concern was that nitroglycerin-induced uterine relaxation might increase blood loss. Although there was no evidence that blood loss was higher with nitroglycerin, women randomised to nitroglycerin were more likely to receive a blood transfusion. Given that there was no significant difference in drop in haemoglobin between groups ([Table 4](#pmed.1003001.t004){ref-type="table"}), we are unclear why administration of nitroglycerin was associated with an increased transfusion rate. However, we speculate that the haemodynamic changes caused by nitroglycerin administration might have altered clinician behaviour in favour of transfusion.

In conclusion, our trial indicates that sublingual nitroglycerin spray is neither clinically effective nor cost-effective for medical treatment of retained placenta when used with controlled cord traction following vaginal delivery and should not be used for this indication. Of note, among women whose placenta remained undelivered 15 minutes after administration of the study drug, over 80% in both study groups were required to go to theatre for MROP. There therefore remains a need for an effective, acceptable, safe, and affordable medical treatment for retained placenta, particularly for low- and middle-income countries, where MROP in theatre is often not available.
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20 Sep 2019

Dear Dr. Denison,

Thank you very much for submitting your manuscript \"Glyceryl trinitrate for treatment of retained placenta: a randomized, placebo-controlled, multicentre double blind trial\" (PMEDICINE-D-19-02549) for consideration at PLOS Medicine.

Your paper was evaluated by a senior editor and discussed among all the editors here. It was also discussed with an academic editor with relevant expertise, and sent to three independent reviewers, including a statistical reviewer. The reviews are appended at the bottom of this email and any accompanying reviewer attachments can be seen via the link below:

\[LINK\]

In light of these reviews, I am afraid that we will not be able to accept the manuscript for publication in the journal in its current form, but we would like to consider a revised version that addresses the reviewers\' and editors\' comments. Obviously we cannot make any decision about publication until we have seen the revised manuscript and your response, and we plan to seek re-review by one or more of the reviewers.

In revising the manuscript for further consideration, your revisions should address the specific points made by each reviewer and the editors. Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments, the changes you have made in the manuscript, and include either an excerpt of the revised text or the location (eg: page and line number) where each change can be found. Please submit a clean version of the paper as the main article file; a version with changes marked should be uploaded as a marked up manuscript.

In addition, we request that you upload any figures associated with your paper as individual TIF or EPS files with 300dpi resolution at resubmission; please read our figure guidelines for more information on our requirements: <http://journals.plos.org/plosmedicine/s/figures>. While revising your submission, please upload your figure files to the PACE digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <PLOSMedicine@plos.org>.

We expect to receive your revised manuscript by Oct 04 2019 11:59PM. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

We ask every co-author listed on the manuscript to fill in a contributing author statement, making sure to declare all competing interests. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. If new competing interests are declared later in the revision process, this may also hold up the submission. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT. You can see our competing interests policy here: <http://journals.plos.org/plosmedicine/s/competing-interests>.

Please use the following link to submit the revised manuscript:

<https://www.editorialmanager.com/pmedicine/>

Your article can be found in the \"Submissions Needing Revision\" folder.

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see <http://journals.plos.org/plosmedicine/s/submission-guidelines#loc-methods>.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

We look forward to receiving your revised manuscript.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)

\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\-\--

Requests from the editors:

1\. The following outcomes measures pertaining to the economic outcomes appear to differ between the submitted manuscript and the trial registry. Please clarify and explain the discrepancy. If the outcomes were not prespecified in the protocol, please indicate that they were post hoc and explain why they were added. Post hoc comparisons should be presented as hypothesis generating rather than conclusive.

Specifically, a primary economic outcome of comparing GTN vs standard practice in terms of net incremental cost to UK NHS (page 7, Lines 174-176). However, the following primary and secondary outcomes included in the trial registry are slightly different (<http://www.isrctn.com/ISRCTN88609453>): Primary outcome: 4. Economic: net incremental costs (or cost savings) to the National Health Service of using GTN versus standard practice. Costs will include GTN (dose and time to administer drug, monitor woman and deliver the placenta if effective), MROP, and further health service resource use as measured by the 6-week postnatal questionnaire; Secondary outcome: 2. Costs: the mean costs will be summarised by treatment allocation group, and the incremental cost (cost saving) associated with the use of GTN will be estimated using an appropriately specified general linear model. The cost data will be presented alongside the primary and secondary outcome data in a cost-consequence balance sheet, indicating which strategy each outcome favours (6-week postnatal questionnaire).

2\. Title: Please make it clear in the title that the trial took place in the UK.

3\. Abstract Line 44: October 14 should be October 2014.

4\. Abstract Line 43-44: The second instance of "was undertaken" is a typo- please correct. Also, "29 delivery units" should read "at 29 delivery units".

5\. Abstract Results: Please quantify the main results (with 95% CIs and p values) for the adverse outcomes presented (e.g. palpitations, adverse events).

6\. Abstract methods and results: Please indicate the outcomes assessed at follow up, and length and method of follow up.

7\. Abstract methods and results: Please indicate the locations (i.e. in which cities) of the maternity wards involved in the study.

8\. At this stage, we ask that you include a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract. Please see our author guidelines for more information: <https://journals.plos.org/plosmedicine/s/revising-your-manuscript#loc-author-summary>

9\. Methods and Results: Please provide further detail regarding the size and other relevant characteristics of the 29 maternity wards included in the study, including how the hospitals were chosen.

10\. Methods and Results: The questionnaire administered at hospital discharge and 6 week follow up (mentioned at lines 161-163) should be included as a supporting document. Please include a file containing the questionnaire, and provide a reference to it in the text.

11\. Line 188: Please clarify the identity of the Chief Investigator.

12\. Line 188: Please clarify the identity, location, and the role of the "Trial Office".

13\. Line 225: Please remove the discussion of the cost analysis. Because the results of the trial were negative it is not necessary.

14\. Line 239: Please remove the section "Role of the Funding Source" from the main text. This is not needed as the information will be automatically extracted from the manuscript submission data.

15\. Methods and Results: Please be consistent with numbers of decimal places when reporting p values. In general, use two decimal places for p\>.01 and three decimal places for p\<.01 (e.g. Table 2 vs. Table 4).

16\. Discussion: Please qualify the first sentence of the discussion with the phrase "to our knowledge" or similar. (Line 339: "GOT-IT is the largest multi-centre, randomised, trial\...")

17\. Discussion, Line 384: Please clarify what is meant by, and the role of the "lay advisors" mentioned.

18\. Discussion: Please elaborate more on where and why the results may differ from previous research/studies of nitroglycerin treatment for retained placenta.

19\. Throughout the manuscript: Please use square brackets "\[\]" for in-text reference numbers, rather than parentheses. Formatting guidelines can be found at: <https://journals.plos.org/plosmedicine/s/submission-guidelines#loc-references>

20\. For Supplementary Figures 1 and 2, please specify in the X axis label that 'Sample Size' denotes number of participants.

21\. CONSORT checklist: Thank you for including the CONSORT checklist. However, some of the page numbers are inconsistent, please double check and update throughout (e.g. Eligibility criteria for participants seem to be described on page 6, rather than page 7-10 as indicated).

Comments from the reviewers:

Reviewer \#1: This is, by far, the largest reported trial of glyceryl trinitrate (GTN) for treatment of retained placenta (RP) and the only trial of sub-lingual spray. The methodological quality of the trial is strong. I don\'t understand some of the statistical methods, but recognise that these will be reviewed by a statistical referee. The trial clearly needs to be published somewhere prominent, where it will be noticed.

I do, however, think that the reporting of the trial could in some respects be improved.

The relevant Cochrane review by Abdel-Aleem and colleagues (2015) - strangely uncited in the paper (it should be) - describes 3 randomised trials of GTN for RP (2 sub-lingual tablets, 1 intravenous); the combined incidence of manual removal of placenta (MROP) in the control groups was 80% and even though two of the trials had slightly more conservative time criteria for intervention (40 and 50 minutes) than GOT-IT, it is difficult to understand why the trial team planned on the basis of 50% MROP in the control group. This mis-match is only addressed in the paper in relation to the decision-making of the data monitoring committee in light of the unexpected incidence of the primary outcome. This should be discussed more fully.

On a related topic, retained placentas are thought to either be detached but retained in the uterus (and potentially amenable to delivery after GTN relaxes uterine muscle) or non-detached (and much less likely to be aided by GTN). I don\'t know if there are good data on the incidence of each. My clinical impression is that the latter are much more common. I think these pathophysiological considerations need to be discussed in more depth to clarify the rationale for the trial, and to refine the discussion about sample size calculation.

The rationale for the treatment regimen is not discussed in much detail other than saying that this was what the funder wanted for this commissioned research call. There are presumably data on bio-equivalence with other GTN regimens from eg internal medicine research. Why this treatment at this dosage? What evidence prior to trial commencement that this is efficacious? Current discussion could be expanded.

There are several references to the importance of RP in low and middle income countries. The authors are correct to emphasise this. They might wish to expand a little on where they saw GTN having a possible role (should it have proven effective). Manual removal of placenta is one of the functions of the Basic Emergency Obstetric Care package, but access to health centres can often be problem. Did they see a potential role for medical intervention for RP in community care or in health centres or both?

Surely the trial entry criterion \'delivery \> 14 weeks\' is a mistake (line 131)?

Jim Neilson

Reviewer \#2: This manuscript reports the results of a RCT comparing Glyceryl trinitrate to placebo for the treatment of retained placenta. The manuscript is well written and very easy to follow. I only have minor comments listed below:

\* In the method section, please indicate the nominal type-I error rate available at the end of the trial given the overall 5% level and the 5 interim reviews planned

\* East 6.4.1 was used to analyse the primary clinical outcome. Please clarify the method (model, adjustment) used for the primary clinical outcome. In particular, please clarify whether the model adjust for the effect of centre?

\* Please confirm that all patients with a CRF available post-discharge also had a primary outcome (MROP use) available

\* The footnote in Table 2 states that \"the analysis was adjusted for multiple looks at the data\". Please clarify what this means. E.g. where the confidence intervals adjusted? the p-values? Is this true for all analyses presented in Table 2 or only the primary clinical outcome?

\* The discussion states (lines 356-357) that \"none of the efficacy and futility boundaries were crossed at any of the interim analysis\" (a similar statement is made in lines 269-270); however, according to supplementary Figure 2, the futility boundaries were crossed at the 4th interim analysis. Please clarify/correct as well as explain more clearly this apparent inconsistency.

-Laurent Billot

Reviewer \#3: This is a very well-written and well-desisgned trial. The clarity in writing and transparency in reporting is commendable.

I have only minor recommendations for this manuscript, which are as follows:

1\) In the title or abstract, please include the term \"nitroglycerin,\" to ensure broader understanding of glyceryl-trinitrate (GTN) as \"nitroglycerin\" is the more common term used in the U.S. and other countries. Consider changing the abbreviation \"GTN\" as this is commonly used to represent \"gestational trophoblastic neoplasia\"

2\) Lines 38-39 and 79-80: the authors discuss that the only alternative management for retained placenta is manual removal, and do not discuss curettage, a commonly performed procedure for retained placenta. This, too, may not be available in lower resource settings, but deserves mention

3\) Lines 95-96: The authors correctly mention that glyceryl trinitrate may be effective for retained placenta in the presence of a contraction ring. The authors appear to have used the medication as a solo measure. A limitation of this study that is not mentioned, but that is more clinically relevant is how often nitroglycerin was needed to allow a contraction ring to relax sufficiently to allow passage of the providers hand to complete manual removal of the placenta, followed by uterotonics and therefore, reduce blood loss. With this in mind, I recommend that the authors consider modifying their conclusion to state that glyceryl trinitrate is neither clinically effective nor cost effective when used alone, and either provide evidence that it is ineffective in this very clinically relevant subset or mention that it may still be considered in this setting, absent other recourse.

Any attachments provided with reviews can be seen via the following link:

\[LINK\]

10.1371/journal.pmed.1003001.r002
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1 Nov 2019

Dear Dr. Denison,

Thank you very much for re-submitting your manuscript \"Glyceryl trinitrate for treatment of retained placenta: a randomized, placebo-controlled, multicentre double blind trial\" (PMEDICINE-D-19-02549R1) for review by PLOS Medicine.

I have discussed the paper with my colleagues and the academic editor and it was also seen again by one reviewer. I am pleased to say that provided the remaining editorial and production issues are dealt with we are planning to accept the paper for publication in the journal.

The remaining issues that need to be addressed are listed at the end of this email. Any accompanying reviewer attachments can be seen via the link below. Please take these into account before resubmitting your manuscript:

\[LINK\]

Our publications team (<plosmedicine@plos.org>) will be in touch shortly about the production requirements for your paper, and the link and deadline for resubmission. DO NOT RESUBMIT BEFORE YOU\'VE RECEIVED THE PRODUCTION REQUIREMENTS.

\*\*\*Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.\*\*\*

In revising the manuscript for further consideration here, please ensure you address the specific points made by each reviewer and the editors. In your rebuttal letter you should indicate your response to the reviewers\' and editors\' comments and the changes you have made in the manuscript. Please submit a clean version of the paper as the main article file. A version with changes marked must also be uploaded as a marked up manuscript file.

Please also check the guidelines for revised papers at <http://journals.plos.org/plosmedicine/s/revising-your-manuscript> for any that apply to your paper. If you haven\'t already, we ask that you provide a short, non-technical Author Summary of your research to make findings accessible to a wide audience that includes both scientists and non-scientists. The Author Summary should immediately follow the Abstract in your revised manuscript. This text is subject to editorial change and should be distinct from the scientific abstract.

We expect to receive your revised manuscript within 1 week. Please email us (<plosmedicine@plos.org>) if you have any questions or concerns.

We ask every co-author listed on the manuscript to fill in a contributing author statement. If any of the co-authors have not filled in the statement, we will remind them to do so when the paper is revised. If all statements are not completed in a timely fashion this could hold up the re-review process. Should there be a problem getting one of your co-authors to fill in a statement we will be in contact. YOU MUST NOT ADD OR REMOVE AUTHORS UNLESS YOU HAVE ALERTED THE EDITOR HANDLING THE MANUSCRIPT TO THE CHANGE AND THEY SPECIFICALLY HAVE AGREED TO IT.

Please ensure that the paper adheres to the PLOS Data Availability Policy (see <http://journals.plos.org/plosmedicine/s/data-availability>), which requires that all data underlying the study\'s findings be provided in a repository or as Supporting Information. For data residing with a third party, authors are required to provide instructions with contact information for obtaining the data. PLOS journals do not allow statements supported by \"data not shown\" or \"unpublished results.\" For such statements, authors must provide supporting data or cite public sources that include it.

If you have any questions in the meantime, please contact me or the journal staff on <plosmedicine@plos.org>.

We look forward to receiving the revised manuscript by Nov 08 2019 11:59PM.

Sincerely,

Caitlin Moyer, Ph.D.

Associate Editor

PLOS Medicine

[plosmedicine.org](http://plosmedicine.org)
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Requests from Editors:

1.Response to reviewer comments: Thank you for your response to Reviewer 1, point 2 (R1, C2) concerning your rationale for assuming a 50% rate of MROP in the control group. Please also clarify this rationale in the manuscript, also, either in the Statistical Analyses section of the Methods or elsewhere as appropriate.

2.Data Availability Statement: Thank you for noting that data cannot be shared publicly, and providing a link for requesting access to data. However, this link connects with a very general web page. If possible, please provide a more specific link and/or a contact email address to facilitate access to data.

3.Abstract: Background: Please define the abbreviation (RP) at first use.

4.Abstract: Line 68: "There were however no difference in questionnaire return rates...": Please revise to "There were however no differences in questionnaire return rates...".

5.Abstract: Methods and Findings: Please state that analysis was intention to treat.

6.Abstract: Methods and Findings: Please provide the number in each group.

7.Abstract: Conclusions: Please address the study implications without overreaching what can be concluded from the data; the phrase \"In this study, we observed \...\" may be useful. Please interpret the study based on the results presented in the abstract, emphasizing what is new without overstating your conclusions. Specifically, please revise the first sentence to: "In this study, we found that nitroglycerin is neither clinically-effective nor cost-effective as a medical treatment for retained placenta, and has increased side effects, suggesting it should not be used." or similar.

8\. Author Summary: "Why was this study done?": Please revise the first point to clarify what is meant by "clinically important" bleeding, for example: "A retained placenta can cause life-threatening bleeding in women following a vaginal birth" or similar.

9\. Author Summary: "What do these findings mean?": Please clarify the first bullet point to: "Our findings indicate that sublingual nitroglycerin does not effectively reduce the need for women with a retained placenta following vaginal delivery to have the placenta removed by an operation." or similar.

10\. Author Summary: "What do these findings mean?": Please revise the second bullet point to: "These findings indicate that there remains a need for a new, safe, and effective medical treatment for retained placenta for those women who live in settings where operative treatment for retained placenta is not available." or similar.

11\. Introduction: Line 105-108: Please provide some reference(s) for the sentence describing how surgical MROP is not available in LMIC.

12\. Methods: Line 153: Please change "hospital" to "hospitals".

13\. Methods: Line 165: Please revise to "We excluded\...placenta accreta/increta/percreta; allergy, hypersensitivity, or contra-indication to nitrates; alcohol...".

14\. Methods: Line 223: Please clarify to "\...collated and coded by the Trial Office, which was located in the Queen's Medical Research Institute..." or similar.

15\. Methods: Line 227: Please clarify to: "The Chief Investigator (Fiona Denison) had regular oversight of the trial office." or similar.

16\. Results: Line 314: "Placebo" should not need capitalization.

17\. Results: Line 318-319: Please indicate which values correspond to nitroglycerin vs. placebo groups for the blood loss outcomes.

18\. Results: Line 325-326: Please indicate which values correspond to nitroglycerin vs. placebo groups for the patient satisfaction outcomes.

19\. Results: Line 328 and 330: Please indicate which values correspond to nitroglycerin vs. placebo groups for the palpitations/heart racing outcomes.

20\. Results: Line 348 and 350: Please indicate which values correspond to nitroglycerin vs. placebo groups for the blood pressure and blood transfusion outcomes.

21\. Discussion: Line 454: Please clarify the use of the term "significant" used in this context. If statistical significance is indicated, please consider revising to: "Given that there was no significant difference in drop in haemoglobin between groups (Table 4), we are unclear...".

22\. Discussion: Line 406-408: Thank you for your response to editor request C18. However, Please provide references and expand on how your findings specifically are in contrast to the previous publication findings (i.e. the sentence beginning "In contrast to previous publications...").

23\. Discussion: Line 382: Please remove the sentence "Our trial was highly successful."

24\. Discussion: Line 388-389: Please revise to "As none of the efficacy and futility boundaries were crossed at any of the interim analyses, the trial was allowed to recruit to its full sample size..." or similar to clarify the meaning.

25\. Discussion: Line 413-414: Please revise to "\...the requirement for cannulation limits its generalisability..."

26\. Discussion: Lines 424-425 (and throughout): Please consistently use either "retained placenta" or the abbreviation "RP" throughout the manuscript, defining the abbreviation at first use.

27\. Discussion: Line 438: Thank you for clarifying the consulting role of the lay advisors in response to editor request C17. Please mention somewhere in the manuscript why and how lay advisors were involved with the study.

28\. Table 1: Please define the abbreviations for "bpm" and "SD" in the table footnote.

29\. Table 2: Please define the abbreviation for "CI" in the table footnote. Please describe in the table footnote the adjustment for multiple looks at the data.

30\. Table 3: Please define the abbreviations for "CI" and "SD" in the table footnote.

31\. Table 4: Please define the abbreviation for "CI" in the table footnote.
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33\. Supplementary Table 7: Please define the abbreviation "bpm" in the table footnote.

34\. Checklist: Thank you for providing the CONSORT checklist. At this time please replace the page numbers with paragraph numbers per section (e.g. \"Methods, paragraph 1\"), as the page numbers of the final published paper may be different from the page numbers in the current manuscript.
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